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Psychoactive pharmaceuticals have been found as teratogens at clinical dosage during pregnancy. These
pharmaceuticals have also been detected in minute (ppb) concentrations in drinking water in the US, and
are environmental contaminants that may be complicit in triggering neurological disorders in genetically
susceptible individuals. Previous studies have determined that psychoactive pharmaceuticals (ﬂuoxetine,
venlafaxine and carbamazepine) at environmentally relevant concentrations enriched sets of genes
regulating development and function of the nervous system in fathead minnows. Altered gene sets were
also associated with potential neurological disorders, including autism spectrum disorders (ASD). Sub-
sequent in vitro studies indicated that psychoactive pharmaceuticals altered ASD-associated synaptic
protein expression and gene expression in human neuronal cells. However, it is unknown if environ-
mentally relevant concentrations of these pharmaceuticals are able to cross biological barriers from
mother to fetus, thus potentially posing risks to nervous system development. The main objective of this
study was to test whether psychoactive pharmaceuticals (ﬂuoxetine, venlafaxine, and carbamazepine)
administered through the drinking water at environmental concentrations to pregnant mice could reach
the brain of the developing embryo by crossing intestinal and placental barriers. We addressed this
question by adding 2H-isotope labeled pharmaceuticals to the drinking water of female mice for 20 days
(10 pre-and 10 posteconception days), and quantifying 2H-isotope enrichment signals in the dam liver
and brain of developing embryos using isotope ratio mass spectrometry. Signiﬁcant levels of 2H
enrichment was detected in the brain of embryos and livers of carbamazepine-treated mice but not in
those of control dams, or for ﬂuoxetine or venlafaxine application. These results provide the ﬁrst evi-
dence that carbamazepine in drinking water and at typical environmental concentrations is transmitted
from mother to embryo. Our results, combined with previous evidence that carbamazepine may be
associated with ASD in infants, warrant the closer examination of psychoactive pharmaceuticals in
drinking water and their potential association with neurodevelopmental disorders.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Multiple studies have identiﬁed a strong genetic component to
the manifestation of neurodevelopmental disorders such as autismSciences, Idaho State Univer-
07, USA
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arbalis), mthomas@isu.eduspectrum disorders (ASD) [1e3] that nonetheless can account only
for a subset of diagnosed cases. In addition, the presence of indi-
vidual low risk contributing susceptibility genes, or common vari-
ants [3] may not sufﬁce as causal agents without the interaction
with other environmental, epigenetic, or stochastic factors to cause
ASD [4e6]. These ﬁndings suggest that a majority of cases may
result from the presence of unknown environmental triggers in
genetically susceptible individuals [1,5e7]. Additional studies have
provided evidence that maternal environmental exposures (espe-
cially in the ﬁrst trimester of pregnancy) play a role in the etiology
of ASD [1,7]. These studies have added to a relatively smaller but
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contaminants in the etiology of neurodevelopmental disorders
[1,3].
In industrialized countries, humans are exposed to nearly 3000
synthetic compounds through daily use and the environment [1,8].
For many of these compounds it remains poorly understood how
their presence in water, air, and/or food affect human health [1,8]
and to what extent they may contribute to neurological disorders
in susceptible individuals [6,7]. Pharmaceuticals and personal care
products (PPCPs) are some of the largest and most widely used
classes of synthetic compounds. These products include commonly
prescribed pharmaceuticals, phthalates in cosmetics, bis-phenol A
(BPA) in plastics and other teratogenic chemicals [1]. Among PPCPs,
our laboratory has been studying psychoactive pharmaceuticals
(including ﬂuoxetine, venlafaxine and carbamazepine) as potential
neurological disorder-relevant contaminants that have been
detected in the drinking water [8,9].
Psychoactive pharmaceuticals (PPs) are widely prescribed [9]
and, following excretion from patients, found in water discharged
from waste-water treatment plants (WWTP) [8,10]. The excreted
products of PPs are metabolically active and have long half-lives
[8,10]. The pharmaceuticals reach surface waters after inefﬁcient
ﬁltration at WWTP and thereafter reach drinking water through
ground-water or other supply routes [8,10].
We studied psychoactive pharmaceuticals such as ﬂuoxetine,
venlafaxine and carbamazepine, as they are among the most
commonly prescribed antidepressants [9]. In addition, at clinical
doses these drugs have demonstrated effects on the prevalence of
autism spectrum disorders (ASDs) [9]. Clinical studies have re-
ported that 1.8%e2.8% of women consume antidepressants during
their pregnancy [11] and prenatal exposure to these antidepres-
sants is linked to increased risk of ASD in infants [12]. Furthermore,
at clinical doses, anti-epileptic drugs (AEDs), such as carbamaze-
pine, have well-studied teratogenic effects [13]. A group of re-
searchers examined infants exposed to carbamazepine during
prenatal development and found them to have lower IQ scores and
impaired cognitive function compared to non-exposed infants [14].
To determine if these PPs alter neurophysiology at concentra-
tions found at WWTP, our lab carried out preliminary studies by
treating juvenile fathead minnow ﬁsh with pharmaceuticals
(ﬂuoxetine, venlafaxine and carbamazepine) at environmentally
relevant concentrations, which were 6e10 times higher than con-
centrations measured in drinking water throughout the US [8,9].
The increase was chosen to accommodate for the various byprod-
ucts and modiﬁed forms of each drug as they occur in the envi-
ronment and to account for the cumulative effects of multiple drugs
[8,9]. Using DNA microarray-based expression proﬁling of exposed
ﬁsh brains, we found that PP-treated water signiﬁcantly induced
the expression of gene sets associated with neuronal growth,
development, regulation, and neurological disorders (including
idiopathic autism) [8,9].
Recent studies have found that in utero exposure to PPs like
antipsychotics, antidepressants and benzodiazepines during preg-
nancy may result in the development of neurologic, respiratory,
gastro-intestinal and autonomic abnormalities in newly born in-
fants [11]. These pharmaceuticals can be grouped into selective
serotonin reuptake inhibitors (SSRI), such as ﬂuoxetine; serotonin-
norepinephrine reuptake inhibitors (SNRI), such as venlafaxine;
mood stabilizers, such as valproate and carbamazepine; and ben-
zodiazepines, such as diazepam, temazepam and nitrazepam
[11,15]. Studies from human subjects have reported the placental
transfer of antidepressants (ﬂuoxetine, sertraline, nortriptyline,
and desmethyl clomipramine) to umbilical cord blood [16,17] when
taken from mothers at clinical dosage, providing evidence that
these antidepressants can cross the intestinal and placental barriers[16,17]. It is unknown, however, if these psychoactive pharmaceu-
ticals can also cross intestinal and placental barriers when ingested
at concentrations observed in drinking water, a question of rele-
vance to all pregnancies where contaminated drinking water may
be consumed.
In the present study, we hypothesized that PPs (ﬂuoxetine,
venlafaxine and carbamazepine) consumed by pregnant mothers at
typical environmental concentrations would cross the intestinal
and placental barriers, and reach the brain of the developing em-
bryos. To determine this, we dissolved deuterium-labeled PP in the
drinking water of pregnant mice and measured deuterium (2H)
enrichment in the developing embryonic brains and maternal
livers. We found carbamazepine, but not ﬂuoxetine or venlafaxine
in both tissues conﬁrming its passage through biological barriers
during pregnancy.
2. Materials and methods
2.1. Ethics statement
All experiments were approved by the Institutional Animal Care
and Use Committee (IACUC) of Idaho State University and per-
formed in accord with the NIH (National Institutes of Health) Guide
for the Care and Use of Laboratory Animals.
2.2. Drug treatments
Fluoxetine D6-oxalate (FLX) [#F919; 98 atom (at) % 2H], Carba-
mazepine (CBZ) [# DLM-2806-1.2; 98 at % 2H], Venlafaxine (VNX)
[#V009; 98 at % 2H] and L-glutamic acid [# DLM-556-0.05; 98 at %
2H] were obtained from Cambridge Isotope Laboratories Inc. (MA).
The overall experimental design comprised ﬁve treatments: FLX
(concentration¼ 10 mg/l; n¼ 4), VNX (50 mg/l; n¼ 4), CBZ (100 mg/l;
n ¼ 4), control (no treatment; n ¼ 4) and negative control
(contaminatedwith 2H-labeled L-glutamine; n¼ 1). To examine the
possibility of embryonic tissue contamination by maternal blood
during dissection, we performed control experiments by bathing
dissected embryos in phosphate buffer saline (PBS) containing
0.03 mg/ml 2H-labeled L-glutamine solution followed by 7e8
washes with PBS. Subsequent measurements of embryonic tissue
resulted in no detection of 2H leading us to adopt the same method
for experimental dissections.
2.3. Animal experiments
Female and male C57BL/6 mice (50 days old) were obtained
from the Jackson Laboratory (Sacramento, CA) and placed on a
standard chow diet for two weeks prior to experiments. Each
experiment was ~20 days long. Starting at Day 1 and for the entire
duration of the experiment, four female mice were given water
containing isotope-labeled pharmaceuticals ad libitum. Water bot-
tles were protected from light to avoid any photo-degradation of
pharmaceuticals and the level of water was monitored daily con-
ﬁrming uniform consumption across test groups. On day 10, each
female was housed with one male and examined for vaginal plug
presence over the following ﬁve days. The day when a plug was
observed wasmarked as embryonic day 0 (E0) of the pregnancy. On
embryonic day 10 (E10), prior to the formation of the bloodebrain
barrier (BBB), pregnant mice were euthanized by CO2 asphyxiation
followed by cervical dislocation. In each dissection, we collected a
lobe of the mother's liver and brains of all embryos. Each embryo
was separated from extraembryonic membranes and micro-
dissected under ice cold PBS to remove the brain. Using a disecting
microscope, we removed embryonic brains using a knife. Thus, we
collected one maternal liver (a lobe) and ﬁve embryonic brains
Fig. 1. Liver d2H values in samples from maternal mice: Pregnant mice were treated
with CBZ, FLX, VNX and compared to untreated controls. Liver samples from CBZ
(100 mg/l; n ¼ 3; p < 0.001) were signiﬁcantly 2H enriched relative to controls. Data
were analyzed using mixed effect ANOVAs followed by Dunnett's post-hoc tests. Error
bars represent SEMs. Asterisks indicate signiﬁcant differences compared to controls
after Dunnett's adjustment for family-wise type I error at signiﬁcance level:
“***” ¼ 0.001. Numbers at the top of each bar represent the sample size.
Fig. 2. Levels of d 2H in embryonic brain samples: In different treatments, female
pregnant mice were treated with CBZ, FLX, VNX and untreated controls. Embryonic
brain samples from CBZ treatment (100 mg/l; n ¼ 3) were signiﬁcantly 2H-enriched
(signiﬁcant level “***” ¼ 0.001) relative to controls. Data were analyzed using a mixed
effect ANOVA followed by Dunnett's post-hoc comparisons of treatments to controls.
Error bars represent SEM. Numbers at the top of each bar indicate the number of
maternal mice and the number of analyzed embryos (in parentheses).
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stored in cryogenic vials in liquid nitrogen, subsequently dried
using a vacuum concentrator (Labconco) for 6 h, and further dried
by incubation at 50 C overnight. Dried samples were stored in
sealed tubes within a desiccation chamber to prevent absorption of
atmospheric water.
2.4. Isotopic analysis
Dried tissue samples (embryonic brain and maternal liver) were
analyzed for 2H enrichment. Samples were weighed (typical
weights~ 0.4e0.8 mg) in silver capsules and analyzed using a
ThermoFinnigan High Temperature Conversion Elemental analyzer
(TC/EA) interfaced to a Delta V Advantage isotope ratio mass
spectrometer (IRMS) through the ConFlo IV system and using a
Zero-Blank Autosampler (Costech Analytical, Valencia, CA, USA).
Samples were combusted at 1400 C in a graphite crucible inside a
glassy carbon reactor, and resultant gases separated in a GC column
at 85 C. The resulting hydrogen isotopic ratios (2H/1H), expressed
as d2H, are reported as per mille (‰) values relative to the VSMOW
scale. International/certiﬁed standards (NBS-22, IAEAeCHe7,
methyl ester #Z3) were analyzed concurrent with the samples to
normalize the raw data and monitor accuracy. Precision is esti-
mated to be better than 2‰.
2.5. Statistical analyses
Each treatment and control group contained four female mice
and of each maternal mouse we analyzed ﬁve embryonic brain
samples. For each female mouse, we calculated a mean d2H
VSMOW value from ﬁve embryonic brain samples, and we used
that mean as a true replicate. We quantiﬁed nested effects in the
experimental design (embryo in maternal mouse) using a nested
mixed effect Analysis of Variance (ANOVA). Signiﬁcance in omnibus
pharmaceutical ﬁxed treatment effects were followed by Dunnett
post-hoc analyses comparing treatments to the control. Statistical
analyses were carried out using R statistical platform [18], with
heavy reliance on the packages lmer [19] and asbio [20,21].
3. Results
3.1. Passage through the intestinal barrier: patterns of detected 2H
isotope in liver samples
We hypothesized that PPs at environmental concentrations
would cross the intestinal barrier and reach the maternal circula-
tory system. To address this question, we treated female mice with
one of three pharmaceutical treatments and and compared them to
control without pharmaceutical treatment. We collected one liver
sample from the maternal mouse in each group.
The d2H values in the liver samples of carbamazepine (100 mg/l;
n ¼ 3; p < 0.001) were signiﬁcantly higher than the control mean
(Fig. 1), suggesting that carbamazepine at typical environmental
concentration passed through the intestinal barrier of pregnant
mice. We did not notice signiﬁcant quantities of 2H in the livers of
other treatments and naturally also not in the untreated controls.
3.2. Passage through the placental barrier: patterns of 2H
enrichment in grouped brain samples of developing embryos
Next, we determined the extent to which PPs at environmental
concentrations could cross the placental barrier and reach the
embryonic brain. To accomplish this, we removed and measured
the d2H values for ﬁve embryonic brains at E10 from each pregnant
mouse (true replicates n ¼ 3). We chose as collection day E10 topreempt the formation of the bloodebrain barrier (BBB), which in
mice starts at ~ E12 [22]. Consequently, pregnant females were
sacriﬁced prior to E12 to avoid any stoppage of pharmaceuticals by
the BBB and mimic the physiology of the early human fetus where
Fig. 3. Pictorial representation of the central hypothesis: This conceptual diagram represents the passage of psychoactive pharmaceuticals at environmental concentrations
through biological barriers.
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In factor level comparisons at the level of true replicate, d2H
values in the brain samples of the carbamazepine (100 mg/l; n ¼ 3)
treatment were signiﬁcantly higher than the control (no treatment;
n ¼ 3; p < 0.001; Fig. 2). Detection of labeled carbamazepine at
typical environmental concentration conﬁrms that the pharma-
ceutical crossed the placental barrier and reached the embryonic
brains.
For the FLX and VNX treatments, we observed no signiﬁcant
change in d2H values relative to the control.
4. Discussion
The risks of exposure to commonly available PPs, not through
direct administration, but rather through secondary sources such as
drinking water at much lower concentrations remain largely un-
explored. Nonetheless, risks need to be assessed, as concentration
of these compounds in the environment experience a continuous
rise [1]. Our study explored the hypothesis that PPs can cross bio-
logical barriers in pregnant mice and reach the developing brain,
potentially posing a liability in the incidence of neuro-
developmental disorders. Consistent with this hypothesis, we
detected isotope-labeled carbamazepine in the liver of dams and
brains of developing embryos if given carbamazepine in the
drinking water at typical environmental concentration (100 mg/l)
(Fig. 3).
Carbamazepine is a sodium channel blocker used as an anti-
convulsant to treat bipolar disorder and to inhibit epileptic seizures
[24]. It is also used as a mood stabilizer during pregnancy andmany
studies have documented poor neonatal adaptation in newly born
infants following its consumption by their mothers [11]. Previous
studies had looked at the transfer of carbamazepine at clinical
doses, but not at very low concentrations. In a landmark 1995
pharmacokinetics study, carbamazepine (CBZ) was shown not only
to cross the intestinal barrier but also the blood brain barrier in rats
[25]. More worrisome, studies have also identiﬁed teratogenic ef-
fects of carbamazepine including abnormal embryonic eye devel-
opment upon administration at clinical doses to pregnant mice
[26]. These studies suggest that carbamazepine could be a potent
teratogen during pregnancy. Furthermore, carbamazepine has also
been identiﬁed as an environmental contaminant, on occasion
detected in the drinking water in concentrations even higher than
100 mg/l, which may contribute to neurological disorders [8].
In previous work from our laboratory, treating fathead minnowﬁsh with PP at environmental concentrations [8], we determined
that carbamazepine had the capacity to disrupt a greater set of
protein interaction networks than other pharmaceuticals [27]. The
study employed RNA-Seq based expression proﬁling of treated
versus control brains and was biased for gene sets enriched for ASD
associated genes. Other transcriptome studies from our laboratory
in human neuronal cells examined whether valproate at clinical
dosage can induce changes in the expression of genes associated
with neurological disorders including autism [27]. Valproate, an
anticonvulsant with similar properties to carbamazepine [28], has
been previously found linked to ASD by inducing autism-like
phenotypes in mice [29]. Furthermore, studies in humans have
found that in utero exposure to valproate is associated with higher
risk of ASD [29]. Taken together, these studies suggest that expo-
sure to carbamazepine during pregnancy, even at very low con-
centrations, may pose a liability to the embryo/fetus towards the
development of ASD.
In maternal liver samples (Fig. 1), we did not see enriched d2H
values in treatments other than for carbamazepine. This implies
that ﬂuoxetine and venlafaxine were not metabolized but this may
be limited by the short experimental period. Mice may metabolize
these drugs differently than carbamazepine as observed with other
pharmaceuticals [30]. It is also known that deuterated pharma-
ceuticals are more metabolically stable due to the increased
strength of carbon-deuterium bonds, and thus may be metabolized
slower but persist longer [31]. In the present study, in vivo detection
of carbamazepine traces in the maternal liver and brains occurred
in the offspring of mice given water at typical environmental con-
centrations found in the drinking water. This suggests that carba-
mazepine could act as an environmental contaminant and
potentially trigger ASD-like symptoms in the developing fetus
during pregnancy.
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